Mesna
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | DRUG-MESNA |
|---|---|
| Tipo | Fármaco |
| Aliaces | Meznex |
| Situación | de la Convención, revisados en 2026-05-07 |
| Enfermedades | DIS-BURKITT DIS-SOFT-TISSUE-SARCOMA |
| Fuentes | SRC-ESMO-SARCOMA-2024 SRC-NCCN-STS-2025 |
Datos sobre drogas
| Clase | Citoprotector de tiol uroprotector |
|---|---|
| Mecanismo | Thiol compound that binds and detoxifies urotoxic ifosfamide metabolites in urine, reducing the risk of hemorrhagic cystitis. It is supportive care, not an antineoplastic treatment-selection signal. |
| Dosificación típica | With ifosfamide: commonly administered as a total daily mesna dose proportional to the ifosfamide dose, using IV and/or oral divided dosing according to institutional protocol. Maintain hydration and urine monitoring. |
| Ucrania registrada | Falso |
| NSZU reembolsado | Falso |
Notas
Thin support-drug entity added to resolve ifosfamide-containing regimen component references. Regimen-specific mesna schedules remain authored on the regimen.
Utilizado por
Esquema terapéutico
REG-CODOX-IVAC-PROVEN-CNS- eviQ proven-CNS R-CODOX-M / R-IVAC reference for specialist reviewREG-CODOX-M-IVAC- Dose-modified R-CODOX-M / R-IVAC: high-risk reference without proven CNS disease (eviQ 44...REG-DOXORUBICIN-IFOSFAMIDE-STS- Doxorubicina + ifosfamide (sarcoma de tejido blando, AI tratamiento)